仙琚制药品牌怎么样 申请店铺

外推网助力仙琚制药品牌出海！将品牌入驻外推网，定制仙琚制药品牌推广信息，可以显著提高仙琚制药产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

浙江仙琚制药股份有限公司前身为仙居制药厂，创建于1972年，是国内规模最大、品种最为齐全的甾体药物生产厂家，是国家计划生育药物定点生产厂家、国家火炬计划重点高新技术企业、全国守合同重信用企业、浙江省优秀创新型单位。公司总股本34140万元，占地面积337607平方米，现有员工2000多人，其中工程技术人员占30%，销售人员占36%，是原料药和制剂综合生产厂家。

公司产品独树一帜，主营业务为甾体原料药和制剂的研制、生产与销售。主要生产皮质激素类药物、性激素类药物（妇科及计生用药）和麻醉与肌松类药物三大类。共有近100多个品种。拥有200吨原料药、70亿片片剂、5亿粒胶囊、2亿支水针、1000万支冻干粉针剂、1000万支乳膏剂、1000万袋颗粒剂的生产能力。

公司与中国科学院上海有机所、中国药科大学等20多个国内着名科研院（校），建立了长期的合作关系，并投资建立了浙江仙琚制药技术开发有限公司。近几年，成功地开发了20多个高科技新药品种，取得了近30余项省级以上科研成果。公司的维库溴铵及其制剂（仙林）、米非司酮片（含珠停）与胶囊、复方戊酸雌二醇片、匹多莫德及其制剂等22个产品为国家级新药；维库溴铵及其注射剂项目、匹多莫德原药及颗粒制项目和糠酸莫米松及乳膏项目被列入国家级火炬计划项目；醋酸烯诺酮及其一根型皮下埋植剂被列入"十五"国家科技攻关项目；抗早孕一类新药ZXH951项目列入国家863计划。地塞米松系列产品的"绿色生产技术与示范"列入国家科技支撑计划（获得的国家资助与"863"项目相当）；甲基泼尼松龙为浙江省重大科技攻关项目。抗早孕药物"含珠停"和肌松药物"仙林"是浙江名牌产品。

截止目前，公司已拥有6项专利发明。公司已在6个国家和地区总计23种产品取得了国际认证，其中，泼尼松龙、醋酸泼尼松、醋酸甲羟孕酮、维库溴铵等四个产品通过美国FDA认证。泼尼松龙、醋酸环丙孕酮等两个产品获得法国GMP证书。泼尼松龙通过欧洲COS和韩国KFDA认证。全部产品均已通过国家GMP认证。

公司拥有一支超过700人的制剂产品销售队伍，形成了医院线和OTC线两个完整的销售网络，并摸索出了有效的销售管理和市场推广策略。公司医院线的销售网络已覆盖全国地级市以上的主要医院，与2800多家医院的妇产科和3500多家医院的麻醉科建立了业务联系；OTC线的销售人员管理的药店已达到6万多家。公司国际贸易部已与美国、印度、英国等30多个国家的40多家原料药加工企业、制剂生产厂家和贸易商建立了业务联系。

目前，公司控股和投资了浙江仙居制药销售有限公司等企业。2010年1月12日，公司已正式在深交所挂牌交易，成功登陆资本市场。为实现规模经营，公司分别在浙江省化学原料药基地及仙居工业园区共征地面积254119平方米，作为原料药新产品生产基地。

未来的五年中，公司总体战略将以营销为导向，"先做强后做大"，提升核心竞争力，在提高盈利能力的前提下扩大销售规模。

Zhejiang Xianju Pharmaceutical Co., Ltd., formerly known as Xianju pharmaceutical factory, was founded in 1972. It is the largest and most complete steroid drug manufacturer in China. It is a designated manufacturer of national family planning drugs, a key high-tech enterprise under the national Torch Program, a national contract abiding and trustworthy enterprise, and an excellent innovative unit in Zhejiang Province. The company has a total capital of 341.4 million yuan, covers an area of 337607 square meters, and has more than 2000 employees, including 30% of engineering and technical personnel and 36% of sales personnel. It is a comprehensive manufacturer of APIs and preparations. The company's products are unique, and its main business is the research, production and sales of steroid APIs and preparations. It mainly produces corticosteroids, sex hormones (gynecological and family planning drugs) and anesthetics and muscle pines. There are more than 100 varieties. It has a production capacity of 200 tons of APIs, 7 billion tablets, 500 million capsules, 200 million water needles, 10 million freeze-dried powder injections, 10 million cream and 10 million bags of granules. The company has established long-term cooperative relations with more than 20 famous domestic scientific research institutes (universities) such as Shanghai Institute of organic science, Chinese Academy of Sciences and China Pharmaceutical University, and invested in the establishment of Zhejiang Xianju Pharmaceutical Technology Development Co., Ltd. In recent years, more than 20 high-tech new drug varieties have been successfully developed and more than 30 scientific research achievements at or above the provincial level have been achieved. 22 products of the company, including vecuronium and its preparation (Xianlin), mifepristone tablet (including Zhuting) and capsule, compound estradiol valerate tablet, pidomode and its preparation, are national new drugs; vecuronium and its injection project, pidomode technical product and granule production project, mometasone furoate and cream project are listed in the national torch program project; enolone acetate and one of its products The project of zxh951, a new drug against early pregnancy, was listed in the National 863 program. The "green production technology and demonstration" of dexamethasone series products are listed in the national science and technology support plan (the national funding is equivalent to the "863" project); methylprednisolone is a major science and technology research project in Zhejiang Province. "Hanzhuting", an anti early pregnancy drug, and "Xianlin", a muscle relaxant, are famous brands in Zhejiang Province. Up to now, the company has 6 patent inventions. The company has obtained international certification for 23 kinds of products in 6 countries and regions, including prednisolone, prednisone acetate, medroxyprogesterone acetate, vecuronium and other four products which have passed FDA certification. Prednisolone, cyproterone acetate and other two products obtained the French GMP certificate. Prednisolone is certified by European COS and Korean KFDA. All products have passed the national GMP certification. The company has a sales team of more than 700 pharmaceutical products, formed two complete sales networks of hospital line and OTC line, and explored effective sales management and marketing strategies. The sales network of the company's hospital line has covered major hospitals at prefecture level and above in China, and established business contacts with the gynecology and obstetrics departments of more than 2800 hospitals and the anesthesiology departments of more than 3500 hospitals; the sales staff of OTC line has managed more than 60000 pharmacies. The International Trade Department of the company has established business contacts with more than 40 API processing enterprises, preparation manufacturers and traders in more than 30 countries, such as the United States, India and the United Kingdom. At present, the company holds and invests in such enterprises as Zhejiang Xianju Pharmaceutical Sales Co., Ltd. On January 12, 2010, the company was officially listed on the Shenzhen Stock Exchange and successfully landed in the capital market. In order to achieve large-scale operation, the company has acquired 25419 square meters of land in Zhejiang chemical API base and Xianju Industrial Park respectively as the production base of new API products. In the next five years, the company's overall strategy will be guided by marketing, "strengthen first and then expand", enhance core competitiveness, and expand sales scale on the premise of improving profitability.

本文链接： https://brand.waitui.com/e01e6332a.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加